arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

NovoCure Limited

NVCR Health Care Medical/Dental Instruments
$17.94
Today
as of Sep 4, 16:52 ET
Last 30 days +9.99% Jul 28 → Sep 04
$14.57 $15.55 $16.52 $17.49 $18.47 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$17.53
High
$18.01
Low
$17.47
Volume
$732,039
Avg Vol
$2M
Mkt Cap
$1.8B
P/E (TTM)
—
Beta
—
52w High
$21.45
52w Low
$9.82
Div Yield
—
Shares Out
$116M

Recent Press Releases & News last 60 days · 19 items

Sep 2 · 11:00 PR Business Wire
Novocure Announces Upcoming Investor Events
Aug 28 · 13:55 Zacks
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Aug 20 · 16:00 Zacks
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
▸ Show all 19 press releases & news Free account →

Overview

52-week range
$9.82
$21
70% of range
Avg surprise (last 2)
+20.9%
Avg reaction (last 2)
-9.8%
50% positive
Latest IV / EM
87%
EM ±13.7% · $18 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.62$-0.50$-0.38$-0.25$-0.13 Actual $-0.50Actual $-0.54Actual $-0.46Actual $-0.36Actual $-0.31Actual $-0.28Actual $-0.31Est $-0.47Actual $-0.36Est $-0.39Actual $-0.33Actual $-0.62Actual $-0.13 MarJunSepMarJunSepMar/2025Jun/2025SepMarJun
Revenue vs Net Income Revenue Net income
$-71M$-5M$61M$127M$193M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.13 — — — — financials
Tue Mar 31, 2026Mar 2026 $-0.62 — — — — financials
Tue Sep 30, 2025Sep 2025 $-0.33 — — — — financials
Thu Jul 24, 2025Jun/2025 $-0.36 $-0.39 +7.7% — -24.0% earnings
Thu Apr 24, 2025Mar/2025 $-0.31 $-0.47 +34.0% — +4.4% earnings
Mon Sep 30, 2024Sep 2024 $-0.28 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.31 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.36 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.46 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.54 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.50 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$184M$174M—$167M$159M$155M—$155M
Cost of revenue$41M$39M—$45M$41M$39M—$35M
Gross profit$142M$135M—$122M$117M$116M—$120M
Operating income$-11M$-67M—$-36M$-40M$-38M—$-32M
Net income$-16M$-71M—$-37M$-40M$-34M—$-31M
EPS (diluted)$-0.13$-0.62—$-0.33$-0.36$-0.31—$-0.28

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$94M$88M$94M$342M$150M$127M$164M$185M
Inventory$42M$43M$41M$39M$40M$39M$35M$39M
Total current assets$639M$632M$647M$1.20B$1.08B$1.09B$1.11B$1.10B
Total assets$795M$788M$804M$1.36B$1.25B$1.25B$1.24B$1.22B
Long-term debt————————
Total liabilities$457M$457M$464M$1.02B$896M$887M$881M$861M
Total equity$338M$331M$340M$341M$349M$362M$360M$361M

Implied volatility — last 90 days

41%83%126%168%211% Jun 07 — IV 75% · EM ±10.3%Jun 08 — IV 74% · EM ±9.8%Jun 09 — IV 69% · EM ±8.7%Jun 10 — IV 78% · EM ±9.2%Jun 11 — IV 119% · EM ±13.1%Jun 12 — IV 65% · EM ±6.6%Jun 15 — IV 131% · EM ±9.5%Jun 16 — IV 128% · EM ±7.6%Jun 17 — IV 74% · EM ±3.1%Jun 19 — IV 60% · EM ±13.3%Jun 22 — IV 61% · EM ±12.7%Jun 23 — IV 58% · EM ±12.0%Jun 24 — IV 52% · EM ±10.4%Jun 25 — IV 62% · EM ±12.1%Jun 26 — IV 54% · EM ±10.4%Jun 29 — IV 55% · EM ±9.7%Jun 30 — IV 62% · EM ±10.7%Jul 01 — IV 57% · EM ±9.5%Jul 02 — IV 74% · EM ±11.9%Jul 03 — IV 76% · EM ±11.9%Jul 06 — IV 73% · EM ±10.1%Jul 07 — IV 67% · EM ±8.9%Jul 08 — IV 86% · EM ±10.8%Jul 09 — IV 95% · EM ±11.3%Jul 10 — IV 56% · EM ±6.1%Jul 13 — IV 76% · EM ±6.4%Jul 14 — IV 156% · EM ±11.3%Jul 15 — IV 111% · EM ±6.5%Jul 16 — IV 211% · EM ±8.8%Jul 20 — IV 70% · EM ±16.6%Jul 21 — IV 99% · EM ±23.1%Jul 22 — IV 85% · EM ±19.4%Jul 23 — IV 74% · EM ±16.7%Jul 24 — IV 69% · EM ±15.3%Jul 27 — IV 72% · EM ±15.0%Jul 28 — IV 73% · EM ±14.9%Jul 29 — IV 107% · EM ±21.4%Jul 30 — IV 78% · EM ±15.3%Jul 31 — IV 65% · EM ±12.5%Aug 03 — IV 73% · EM ±12.9%Aug 04 — IV 72% · EM ±12.4%Aug 05 — IV 41% · EM ±6.9%Aug 06 — IV 81% · EM ±13.1%Aug 07 — IV 60% · EM ±9.4%Aug 10 — IV 59% · EM ±8.2%Aug 11 — IV 69% · EM ±9.1%Aug 12 — IV 82% · EM ±10.2%Aug 13 — IV 61% · EM ±7.2%Aug 14 — IV 71% · EM ±7.8%Aug 17 — IV 58% · EM ±4.8%Aug 18 — IV 128% · EM ±9.3%Aug 19 — IV 79% · EM ±4.7%Aug 20 — IV 94% · EM ±3.9%Aug 24 — IV 69% · EM ±14.3%Aug 25 — IV 74% · EM ±15.0%Aug 26 — IV 63% · EM ±12.6%Aug 27 — IV 72% · EM ±14.0%Aug 28 — IV 84% · EM ±16.0%Aug 31 — IV 62% · EM ±11.0%Sep 01 — IV 79% · EM ±13.5%Sep 02 — IV 50% · EM ±8.4%Sep 03 — IV 60% · EM ±9.6%Sep 04 — IV 87% · EM ±13.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in